Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Free Cash Flow (2016 - 2025)

Standard Biotools (LAB) has disclosed Free Cash Flow for 16 consecutive years, with -$22.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 23.09% to -$22.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$94.8 million, a 34.4% increase, with the full-year FY2024 number at -$151.8 million, down 229.18% from a year prior.
  • Free Cash Flow was -$22.2 million for Q3 2025 at Standard Biotools, down from -$15.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$7.5 million in Q4 2021 to a low of -$63.3 million in Q1 2024.
  • A 5-year average of -$22.2 million and a median of -$19.8 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 67.12% in 2023, then crashed 566.21% in 2024.
  • Standard Biotools' Free Cash Flow stood at -$7.5 million in 2021, then crashed by 165.74% to -$19.9 million in 2022, then increased by 29.08% to -$14.1 million in 2023, then tumbled by 51.91% to -$21.5 million in 2024, then dropped by 3.14% to -$22.2 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Free Cash Flow are -$22.2 million (Q3 2025), -$15.8 million (Q2 2025), and -$35.3 million (Q1 2025).